Novel targets for lung cancer therapy: Part I

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2881-2894

  Dy, Grace K ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 628 647; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BEXAROTENE; BRYOSTATIN; CANCER VACCINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CGP 69846A; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; ISIS 2503; ISIS 3521; LONAFARNIB; MIDOSTAURIN; PACLITAXEL; PANITUMUMAB; PD 183085; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEILITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIVER TOXICITY; LUNG CANCER; MYALGIA; NAUSEA; NONHUMAN; ONCOGENE NEU; PANCREATITIS; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA;

DRUG THERAPY; HUMANS; LUNG NEOPLASMS; RECEPTORS, GROWTH FACTOR; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 0037096812     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.145     Document Type: Article

References (111)

1. Advances in the systemic therapy of small cell cancer of the lung
2. Non-small-cell lung cancer: Stalemate or progress?
3. Molecular abnormalities in lung cancer
4. Molecular pathogenesis of lung cancer
5. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer
6. New short-chain analogues of substance P antagonist inhibit proliferation of small-cell-lung-cancer cells in vitro and in vivo
7. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P(6-11) (antagonist G) induces AP- 1 transcription and sensitizes cells to chemotherapy
8. Inhibition of substance P induced vasodilation as a biological endpoint in the phase I trial of antagonist G, a broad spectrum neuropeptide growth factor antagonist
9. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A 431 epidermoid carcinoma cells
10. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors
11. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type
12. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma
13. Epidermal growth factor-related peptides and their receptors in human malignancies
14. Anti-epidermal growth factor receptor monoclonal antibody 225 up- regulates p 27KIP1 and induces G1 arrest in prostatic cancer cell line DU145
15. Antitumor activity of sequential treatment with topotecan and anti- epidermal growth factor receptor monoclonal antibody C 225
16. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C 225 in patients with EGFR overexpressing tumors
17. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas
18. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
19. A single autophosphorylation site confers oncogenicity to the Neu/ErbB- 2 receptor and enables coupling to the MAP kinase pathway
20. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis
21. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression
22. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung
23. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
24. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
25. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: Mechanisms and implications
26. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines
27. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
28. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents
29. Her2 expression and gene amplification in non-small cell lung cancer
30. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
31. Differential responses of human tumor cell lines to anti-p 185HER2 monoclonal antibodies
32. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
33. Phase II eastern cooperative oncology group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): Early analysis of E2598
34. Randomized phase II trial of trastuzumab (Tras) plus either weekly docetaxel (Doc) or paclitaxel (Pac) in previously untreated advanced non-small cell lung cancer (NSCLC)
35. Cisplatin and gemcitabine combined with herceptin in patients (pts) with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): A phase II trial
36. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB 2 receptor on tumor growth
37. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine
38. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study
39. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1), in patients with five selected tumor types: Evidence of activity and good tolerability
40. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours
41. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
42. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD- 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
43. The microtubule-affecting drug paclitaxel has anti-angiogenic activity
44. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK1), in combination with carboplatin and paclitaxel (P) in previously untreated advanced nonsmall cell lung cancer (NSCLC)
45. Initial results from a phase II trial of ZD1839 (IRESSA) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL I)
46. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxy-camptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
47. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
48. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors
49. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
50. A phase II trial of the epidermal growth factor tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer
51. Receptor tyrosine kinase inhibitors
52. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
53. Oncogenic kinase signaling
54. The selective tyrosine kinase inhibitor STI 571 inhibits small cell lung cancer growth
55. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
56. Regulation of protein kinase C and role in cancer biology
57. Potent and specific inhibitors of protein kinase C of microbial origin
58. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent
59. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
60. Phase I trial of 72-hour continuous infusion UCN- 01 in patients with refractory neoplasms
61. Twelves phase I and pharmacokinetic study of PKC 412, an inhibitor of protein kinase C
62. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC 412, an inhibitor of protein kinase C
63. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
64. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance
65. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue
66. Effect of bryostatin-1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
67. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
68. A phase I study of intravenous bryostatin- 1 in patients with advanced cancer
69. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
70. Phase II study of bryostatin-1 in combination with paclitaxel for advanced non-small cell lung cancer (NSCLC)
71. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
72. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer
73. Blocking oncogenic ras signaling for cancer therapy
74. Disruption of the MAP kinase signaling pathway using antisense oligonucleotide inhibitors targeted to ras and raf kinase
75. A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma
76. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer
77. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC)
78. Farnesyltransferase inhibitors
79. Targeting ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies
80. Farnesyl transferase inhibitors: Antineoplastic mechanism and clinical prospects
81. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
82. Farnesyl transferase inhibitors: Potential role in the treatment of cancer
83. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R 115777 in vivo and in vitro
84. Current status of clinical trials of farnesyltransferase inhibitors
85. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777
86. Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: A promising combination in patients (PTS) with solid tumors
87. Phase I study of farnesyl transferase inhibitor SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
88. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
89. Phase I clinical trial of the farnesyltransferase (FF) inhibitor BMS-214662 in patients with advanced solid tumors
90. Clinical trial of mutant ras peptide vaccination along with IL-2 or GM-CSF
91. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
92. A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
93. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
94. Phase I clinical, pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with locally advanced or metastatic cancer
95. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
96. MEK inhibition enhances paclitaxel-induced tumor apoptosis
97. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN- 01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells
98. CI-1040: A novel small molecule MEK inhibitor with broad spectrum antitumor activity
99. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of bad on Ser 136
100. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway
101. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
102. CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule
103. The retinoid signaling pathway: Molecular and genetic analyses
104. Retinoid and apoptosis: Implication for cancer chemoprevention and therapy
105. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
106. Activation of RXR receptors induces apoptosis in HL- 60 cell lines
107. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
108. A phase I study of LGD 1069 in adults with advanced cancer
109. Initial clinical trial of a selective retinoid X receptor ligand, LGD 1069
110. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer
111. Placebo-controlled trial of bexarotene (Targretin capsules, LGD 1069): A retinoid X receptor (RXR) agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small cell lung cancer